

# Andrew J Cowan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9912241/publications.pdf>

Version: 2024-02-01

28  
papers

1,547  
citations

759233

12  
h-index

677142

22  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1826  
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	1.4	436
2	Global Burden of Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1221.	7.1	398
3	Diagnosis and Management of Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 464.	7.4	308
4	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.	1.4	91
5	Pembrolizumab with Râ€CHOP in previously untreated diffuse large Bâ€cell lymphoma: potential for biomarker driven therapy. <i>British Journal of Haematology</i> , 2020, 189, 1119-1126.	2.5	69
6	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. <i>Blood</i> , 2016, 128, 1834-1834.	1.4	42
7	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019, 134, 691-691.	1.4	37
8	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology</i> , 2021, 8, e562-e571.	4.6	28
9	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021, 138, 79-79.	1.4	20
10	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19
11	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020, 136, 45-46.	1.4	19
12	Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1386-1391.	2.0	17
13	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021, 17, 3549-3560.	2.4	10
14	Plasma cell diseases and organ transplant: A comprehensive review. <i>American Journal of Transplantation</i> , 2018, 18, 1046-1058.	4.7	9
15	Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 60-70.	2.1	9
16	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , 2021, 138, 2852-2852.	1.4	7
17	Management of Acute Myeloid Leukemia in the Intensive Care Setting. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 375-384.	2.8	6
18	Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 254-259.	3.0	6

#	ARTICLE	IF	CITATIONS
19	Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 661.e1-661.e6.	1.2	5
20	KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 602-609.	0.4	5
21	High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 1902-1902.	1.4	3
22	Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. <i>Blood</i> , 2021, 138, 2723-2723.	1.4	3
23	Burden of Multiple Myeloma in Taiwan—Reply. <i>JAMA Oncology</i> , 2019, 5, 116.	7.1	0
24	Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas. <i>Blood</i> , 2015, 126, 2728-2728.	1.4	0
25	Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. <i>Blood</i> , 2016, 128, 3577-3577.	1.4	0
26	Frequency of Amyloid Subtyping Among Patients with Immunoglobulin Light-Chain Amyloidosis Referred for High-Dose Chemotherapy and Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5601-5601.	1.4	0
27	Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada. <i>Blood</i> , 2020, 136, 21-21.	1.4	0
28	Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada. <i>Blood</i> , 2020, 136, 20-21.	1.4	0